Clinical Trial Update: Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial evaluating Imatinib Mesylate for malignant peripheral nerve sheath tumors has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Peripheral Nerve Sheath Tumors

Drugs mentioned

• Imatinib mesylate (Imatinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Malignant Peripheral Nerve Sheath Tumors | Phase 2, Phase 3 | Status: TERMINATED